Investors in Boston‑based Moderna saw their holdings surge more than 120% on Wednesday, closing at $140.12 per share, after the biotech firm released early results from a pivotal study of its experimental mRNA cancer vaccine, intismeran. The announcement also lifted Merck’s stock about 11%.
Study design and key findings
The trial, conducted jointly by Moderna and Merck, evaluated intismeran—a personalized mRNA vaccine designed to target unique mutations found in each patient’s tumor—when used together with Merck’s immunotherapy drug Keytruda (pembrolizumab). Researchers compared outcomes for melanoma patients receiving the combination therapy against a control group receiving Keytruda alone.
According to the companies, patients who received both intismeran and Keytruda experienced a longer period without cancer returning or spreading (progression‑free survival) than those treated with Keytruda only. The exact length of that benefit was not disclosed, nor were overall survival figures released.
Implications for cancer treatment
If the early signals hold up in later phases, intismeran could become the first FDA‑approved mRNA‑based cancer vaccine, expanding the technology that has already proven successful in preventing infectious diseases such as COVID‑19. The personalized approach aims to train the immune system to recognize and attack tumor‑specific antigens, potentially offering a new line of defense for patients with hard‑to‑treat cancers.
Both companies said they plan to present the full data at an upcoming international medical conference, where additional details on patient numbers, safety outcomes, and statistical significance will be shared.
Market reaction
The dramatic rise in Moderna’s share price reflects investor optimism that the company can translate its mRNA platform into a broader therapeutic portfolio beyond vaccines for infectious diseases. Merck’s more modest gain suggests confidence in the partnership’s ability to enhance the efficacy of its existing immunotherapy pipeline.
Analysts note that while the early results are encouraging, the market will likely await longer‑term data before assigning a definitive valuation to the partnership’s cancer‑treatment prospects.
What’s next?
Moderna and Merck have indicated that further clinical trials are planned to confirm the benefit of intismeran across additional cancer types and larger patient populations. The companies also intend to explore whether the vaccine can be combined with other checkpoint inhibitors or targeted therapies.
For patients and families facing melanoma, the news offers a hopeful glimpse of future treatment options that could extend disease‑free intervals and improve quality of life. However, experts caution that the therapy remains experimental until it completes the full regulatory approval process.
Original reporting: Alexandria, VA News – WTOP News — read the source article.
